SOURCE: Orgenesis Inc.

Orgenesis Inc.

November 30, 2015 14:05 ET

Orgenesis CEO to Speak on Innovations in Diabetes Panel at IDEA Summit

GERMANTOWN, MD--(Marketwired - Nov 30, 2015) - Orgenesis Inc. (OTCQB: ORGS), a cell therapy and regenerative medicine company with a novel therapeutic technology dedicated to converting a patient's own cells into functioning insulin-producing cells as a treatment for diabetes, today announced its CEO, Vered Caplan, will participate in a panel discussion involving young companies spearheading cutting edge research on advancing Diabetes research.

The panel entitled, "Most successful/innovative start-ups & SMEs in 2014/2015 in Diabetes" will be held at the Innovation in Diabetes: European Action (IDEA) Summit 2015 on Monday, November 30th from 5 p.m. to 6.15 p.m. at Palais de la Musique et des Congres in Strasbourg, France.

This session will feature innovative young diabetes companies as their leaders discuss the challenges they faced throughout their respective journeys from academia to where they are today. The session will be moderated by John Carrol, Editor-in-Chief of FierceBiotech.

The IDEA Summit, co-organized by Lund University, Eurasanté & the Nutrition Health Longevity (NHL) cluster, is an international event dedicated to translational research on diabetes. IDEA Summit gathers 150 attendees coming from all over Europe such as Pharma & Biotech professionals, Academic Scientists, TTOs, VCs, Policy makers, Regulatory & Financing bodies, Biobanks, Patients associations and others. IDEA Summit's 3rd edition will be held on November 30th & December 1st, 2015 in Strasbourg (France), during the BioFIT event. For more details, please visit: http://www.idea-summit-diabetes.com

About Orgenesis Inc.
Orgenesis is a cell therapy and regenerative medicine company that is committed to developing a cure for Type 1 Diabetes. In pursuit of this goal, the company has developed and patented a novel technology called "cellular trans-differentiation" that turns an insulin-dependent patient's own liver cells into functional insulin producing cells. Orgenesis has proven that, when exposed ex-vivo to certain pancreatic transcription factors and in specific sequence, human adult liver cells can be transformed into fully functional, beta cell-like insulin producing cells (IPCs). After ex-vivo expansion, the IPCs are re-infused via the portal vein of the diabetic patient. In pre-clinical models of Type 1 Diabetes (Non-Obese Diabetic mice), the re-introduced IPCs remain in the liver, effectively respond to glucose challenge and successfully maintain glycemic homeostasis. In the same NOD model, the implanted IPCs were not subject to auto-immune attack or cellular ablation. Orgenesis plans to initiate P1/2 trials in the next 12-18 months. Orgenesis believes that converting the diabetic patient's own tissue into insulin-producing cells has the potential to overcome the significant issues of donor shortage, cost and exposure to chronic immunosuppressive therapy associated with islet cell transplantation. For more information, visit www.orgenesis.com.

Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" which are not purely historical. Such forward-looking statements include, among other things, the expectations of management that our regeneration technology can be developed as therapeutic treatment for diabetes which could, if successful, be a cure for Type 1 Diabetes; that we can develop the technology to turn a small number of cells into a large number of cells; and that we will initiate Phase I and Phase II clinical trials in the near-term. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits Orgenesis will obtain from them. Actual results could differ from those projected in any forward-looking statements due to numerous factors, including, among others, the potential failure of development candidates to advance through preclinical studies or demonstrate safety and efficacy in clinical testing; the ability to pass clinical trials so as to move on to the next phase; our technology may not as well as expected, our ability to retain key employees; our ability to finance development and operations; our ability to satisfy the rigorous regulatory requirements for new medical procedures; and competitors may develop better or cheaper alternatives to our products. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Investors should refer to the risk factors disclosure outlined in our periodic reports filed from time-to-time with the Securities and Exchange Commission.

Contact Information